查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1557333

全球癌症分析市場 – 2024 年至 2029 年預測

Global Cancer Profiling Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

癌症分析市場預計將從 2024 年的 318.16 億美元增至 2029 年的 590.49 億美元，複合年成長率為 13.17%。

癌症是細胞不受控制的生長，可能是致命的。環境因素是驅動細胞調節的遺傳密碼變化最常見的原因。細胞突變會導致細胞生長異常並影響鄰近的細胞和器官。癌症或腫瘤分析是一種在腫瘤組織樣本中尋找特定基因或基因突變（變化）、蛋白質或其他生物標記的診斷技術。腫瘤分析用於幫助制定治療計劃並預測癌症是否會復發或擴散到身體的其他部位。

該市場的主要成長要素是全球癌症發生率的上升以及腫瘤分析中生物標記的使用不斷增加。癌症研究的增加、資助計劃以及分析技術的技術開拓也推動了癌症分析市場的成長。此外，對個人化醫療和照護現場的需求不斷成長預計將在整個預測期內為市場參與企業提供重大機會。

癌症分析市場促進因素：

  • 癌症發生率的快速增加對市場成長有正面影響。

如果及早發現並給予適當的治療，許多癌症是可以治癒的，隨著全球癌症盛行率的增加，對癌症分析的需求預計也將顯示出吸引力。因此，目前30-50%的癌症是可以預防的，並且可以透過對癌症患者的早期發現和適當的治療和護理來減輕癌症的負擔。

據世界衛生組織 (WHO) 稱，到 2050 年，全球新增癌症病例數預計將達到 3,500 萬人。這比 2022 年報告的 2,000 萬新病例增加了 77%。肺癌、乳癌、攝護腺癌和大腸癌等主要癌症類型佔全球盛行率的大部分，需要持續治療。

此外，全球人口的成長進一步擴大了癌症分析的總體範圍，尤其是老年人口，從而推動了市場的擴張。根據聯合國資料，2024年世界人口將達到86億，並預計在未來50至60年持續成長，到2080年代中期將達到103億。

  • 癌症分析的積極努力預計將刺激市場成長。

為了最大限度地降低癌症相關死亡的風險並促進精準癌症醫學的發展，各種篩檢和生物技術公司正在著手進行癌症分析。例如，2024 年 4 月，Exact Sciences 與 Mayo Clinic 合作啟動了一項遺傳性癌症檢測和基因組分析舉措。因此，此類舉措擴大了臨床醫生和研究人員的資料收集範圍，以促進患者照護事業。

同樣，2023 年 4 月，安捷倫科技與 Theragen Bio 簽署了一份合作備忘錄，以在韓國推廣精準腫瘤學。根據協議，安捷倫將提供癌症基因組分析設計和軟體專業知識，以支援局部分析和治療決策。

癌症分析市場的地理前景

  • 據估計，北美將佔據重要的市場佔有率。

由於加強加強癌症精準治療，預計北美地區將顯著成長並佔據重要的市場佔有率。為此，美國和其他主要地區正在進行各種投資和研究合作，並進行測試以選擇新的治療方法。例如，2023年2月，Exact Science Corp在美國推出了治療方法選擇測試OncoExTra(TM)。它提供次世代定序以及基於 RNA 和 DNA 的基因組測試，以幫助醫生完成患者的癌症分析。

此外，美國也是癌症發生率上升的主要國家之一。例如，根據美國癌症協會預測，2024年美國癌症新增病例數預計將達到2,001萬例，死亡人數將達611萬例。因此，這意味著新患者增加2.6%，死亡頻率增加1.7%。

靈活的美國政府法規和包括美國國立衛生研究院在內的各種組織的資助，使研究人員能夠發現和開發藥物、檢測腫瘤並監測對癌症治療的生物反應，並在基因生物標記的使用方面進行了大量投資。其他區域經濟體，即加拿大，癌症死亡率也很高。據加拿大癌症協會稱，到2024年，大約有247萬加拿大人將被診斷出患有癌症，導致88,100人死亡。

癌症分析市場的限制因素：

  • 與樣本收集相關的技術問題可能會抑制市場成長。

服務提供者最直接關心的問題之一是樣本收集，然後是對這些樣本的存取。這些樣品受到嚴格的品管，必須妥善管理以避免損失。

此外，篩檢計劃僅對某些癌症類型有效，而不是對所有癌症類型有效。它比早期檢測要困難得多，而且集中大量資源，因為它需要專門的設備和專門的人員。另一方面，高資本投資、手術成本和儲存問題可能會阻礙癌症分析市場的擴張。監管標準不足、報銷選擇以及較低的發現與核准比率預計將為癌症分析市場帶來挑戰。

癌症分析 主要市場開拓

  • 2024 年 6 月，Guardant Health Inc. 宣布推出 Guardant360 TissueNext，這是一項涵蓋 498 個生物標記和推薦基因的組織基因組分析測試。
  • 2024 年 3 月，Transgene、BostonGene 和 NEC 延長了 TG4​​050 I/II 期研究的合作關係。兩家公司將持續進行微環境分析和腫瘤分子分析，向研究人員提供次世代定序資料，並加強開發頸癌和頭癌患者的治療性疫苗。
  • 2024年1月，QIAGEN Digital Insights推出了“QIAGEN CLC Genomics Workbench Premium”，該產品採用光速技術，支援胃癌NGS分析。該解決方案改變了全面基因組分析的遊戲規則，使臨床實驗室能夠針對體細胞應用運行高通量次世代定序儀。

癌症分析市場細分與分析如下：

依技術

  • 免疫組織化學
  • In situ Hybridization
  • 次世代定序
  • 定量聚合酵素鏈鎖反應(qPCR)
  • 質譜分析
  • 微陣列
  • 其他

按癌症類型

  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 黑色素瘤癌症
  • 腎癌
  • 肝癌
  • 其他

按申請

  • 個人化醫療
  • 癌症診斷
  • 癌症研究
  • 生物標記搜尋
  • 治療和監測
  • 其他

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 其他
  • 中東/非洲
  • 沙烏地阿拉伯
  • UAE
  • 南非
  • 其他
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球癌症分析市場：依技術分類

  • 介紹
  • 免疫組織化學
  • 原位雜合技術
  • 次世代定序
  • 定量聚合酵素鏈鎖反應(qPCR)
  • 質譜分析
  • 微陣列
  • 其他

第6章全球癌症分析市場：依癌症類型分類

  • 介紹
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 黑色素瘤癌症
  • 腎癌
  • 肝癌
  • 其他

第7章癌症分析的全球市場：依應用分類

  • 介紹
  • 個人化醫療
  • 腫瘤診斷
  • 癌症研究
  • 生物標記發現
  • 治療和監測
  • 其他

第8章全球癌症分析市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Illumina, Inc.
  • Qiagen NV
  • NeoGenomics Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Genomic Health
  • GE Healthcare
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Hologic Inc.
  • Bio-Rad Laboratories Inc
簡介目錄
Product Code: KSI061612096

The global cancer profiling market is anticipated to reach US$59.049 billion in 2029 from US$31.816 billion in 2024 at a CAGR of 13.17%.

Cancer is an uncontrolled cell proliferation that has the potential to be fatal. Environmental factors are the most common source of changes in gene encoding that prompt cell regulation. Cell mutation causes aberrant cell proliferation, affecting adjacent cells and organs. Cancer or tumor profiling is a diagnostic technique that looks for specific genes or gene mutations (changes), proteins, or other biomarkers in tumor tissue samples. Tumor profiling may be used to aid treatment planning and to predict whether cancer will recur or spread to other areas of the body.

The major growth factors for this market are the rising global prevalence of cancer and the increasing use of biomarkers in tumor profiling. Increased cancer research, funding initiatives, and technical developments in profiling technologies are also driving the cancer profiling market's growth. Furthermore, the growing demand for personalized medicine and point-of-care diagnostics is projected to provide substantial possibilities for market participants throughout the forecast period.

Global Cancer Profiling Market Drivers:

  • The booming cancer prevalence has positively impacted the market growth.

Many cancers have a high chance of being cured if detected early and treated properly, and with the rising global prevalence of cancer, the demand for cancer profiling is also expected to show traction. Hence, between 30 and 50% of cancers can currently be prevented, and the cancer burden can also be reduced through early detection of cancer and appropriate treatment and care of patients who develop cancer.

According to the World Health Organization (WHO), by 2050, the global frequency of new cancer cases is estimated to reach 35 million. It will showcase a 77% growth over 20 million new cases reported in 2022. Major cancer types such as lung, breast, prostate & colorectal cancer account for a major portion of global prevalences and require constant treatment.

Additionally, the bolstering growth in the global population has further raised the overall scope of cancer profiling, especially among the older population, thereby adding more to the market expansion. As per the United Nations data, the global population stood at 8.6 billion in 2024, and for the next 50-60 years, it is expected to grow at a constant rate, thereby reaching up to 10.3 billion by the mid-2080s.

  • Favorable initiatives in cancer profiling are estimated to stimulate market growth.

To minimize the risk of cancer-related deaths and bolster the development of precision cancer medicine, various screening and biotech companies are initiating cancer profiling. For instance, in April 2024, Exact Sciences, in collaboration with Mayo Clinic, launched an initiative for hereditary cancer tests and genomic profiling. Hence, such an initiative will expand the data collection to allow clinicians and researchers to advance their careers in patient care.

Likewise, in April 2023, Agilent Technologies signed a Memorandum of Understanding (MOU) with Theragen Bio to boost precision oncology in South Korea. As per the agreement, Agilent would provide cancer genomic profiling design and software expertise for diving localized analysis and supporting treatment decisions.

Global Cancer Profiling Market Geographical Outlook

  • North America is estimated to constitute a remarkable market share.

The North American region is set to grow significantly and will account for a considerable market share fuelled by the growing efforts to bolster cancer precision treatment. It has led to various investments & research collaboration followed by new therapy selection tests in major regional economies, namely the United States. For instance, in February 2023, Exact Science Corp launched the "OncoExTra(TM)" therapy selection test in the United States. It would provide next-generation sequencing and RNA & DNA-based genomic tests that would assist doctors in completing their patient's cancer analysis.

Additionally, the United States is also one of the major nations where the frequency of cancer is on the rise. For instance, as per the American Cancer Society, for 2024, the estimated strength of new cancer cases in the United States will reach 20.01 million, with several projected deaths reaching 6.11 million. Hence, this signifies a 2.6% growth in new cases and 1.7% in death frequency.

The flexibility of US government regulations and the availability of funds from various organizations, such as the National Institute of Health, has allowed researchers to invest more in the use of biomarkers in drug discovery, drug development, tumor detection, monitoring biological response to cancer therapy, and genetic studies for the identification of cancer-predisposed candidates. Other regional economies, namely Canada, are also showcasing a higher death rate for cancer. As per the Canada Cancer Society, in 2024, approximately 2.47 million Canadians will be diagnosed with cancer, and the death count will reach 88,100.

Global Cancer Profiling Market Restraints:

  • Technical issues regarding sample collection can restrain market growth.

One of the most immediate concerns regarding service providers is sample collection, followed by access to these samples. These samples must be subjected to strict quality control and maintained properly to avoid loss.

Furthermore, screening programs are helpful for only certain types of cancer and not all. They are considerably more difficult and resource-intensive than early detection since they require specialized equipment and committed staff. On the other hand, high capital investment, procedure costs, and storage concerns will likely hinder the expansion of the cancer profiling market. Poor regulatory standards, reimbursement options, and a low discovery-to-approval ratio are expected to challenge the cancer profiling market.

Global Cancer Profiling Key Market Developments

  • In June 2024, Guardant Health Inc. launched its tissue genomic profiling test "Guardant360 TissueNext," which covers 498 biomarkers and recommended genes. This enables oncologists to target therapies and treatment strategies for patients suffering from advanced-level cancer.
  • In March 2024, Transgene, BostonGene, and NEC Corporation extended their collaboration for the Phase I/II trial of TG4050. The companies would continue performing microenvironment analysis and tumor molecular profiling, which would provide next-generation sequencing data to researchers and bolster their efforts to develop therapeutic vaccines for neck and head cancer patients.
  • In January 2024, QIAGEN Digital Insights launched its "QIAGEN CLC Genomics Workbench Premium," which features light-speed technology and supports NGS analysis for stomach cancer. The solution is a game changer for comprehensive genomic profiling and would enable clinical labs to perform high-throughput next-generation sequencing for somatic applications.

The Global Cancer Profiling market is segmented and analyzed as follows:

By Technology

  • Immunohistochemistry
  • In situ Hybridization
  • Next-Generation Sequencing
  • Quantitative Polymerase Chain Reaction (qPCR)
  • Mass Spectrometry
  • Microarrays
  • Others

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Kidney Cancer
  • Liver Cancer
  • Others

By Application

  • Personalized Medicine
  • Oncological Diagnostics
  • Cancer Research
  • Biomarker Discovery
  • Treatment & Monitoring
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL CANCER PROFILING MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Immunohistochemistry
  • 5.3. In situ Hybridization
  • 5.4. Next-Generation Sequencing
  • 5.5. Quantitative Polymerase Chain Reaction (qPCR)
  • 5.6. Mass Spectrometry
  • 5.7. Microarrays
  • 5.8. Others

6. GLOBAL CANCER PROFILING MARKET BY CANCER TYPE

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Lung Cancer
  • 6.4. Colorectal Cancer
  • 6.5. Prostate Cancer
  • 6.6. Melanoma Cancer
  • 6.7. Kidney Cancer
  • 6.8. Liver Cancer
  • 6.9. Others

7. GLOBAL CANCER PROFILING MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Personalized Medicine
  • 7.3. Oncological Diagnostics
  • 7.4. Cancer Research
  • 7.5. Biomarker Discovery
  • 7.6. Treatment & Monitoring
  • 7.7. Others

8. GLOBAL CANCER PROFILING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. UK
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. South Africa
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Illumina, Inc.
  • 10.2. Qiagen N.V.
  • 10.3. NeoGenomics Laboratories, Inc.
  • 10.4. F. Hoffmann-La Roche Ltd
  • 10.5. Genomic Health
  • 10.6. GE Healthcare
  • 10.7. Siemens Healthineers
  • 10.8. Thermo Fisher Scientific Inc.
  • 10.9. Hologic Inc.
  • 10.10. Bio-Rad Laboratories Inc